Aptamer researches applied to the treatment of human cancers have increased since their discovery in 1990. This is due to different
factors including: 1) the technical possibility to select, by SELEX-based procedures, specific aptamers targeting virtually any given
molecule, 2) the aptamer favorable bio-activity in vivo, 3) the low production costs and 4) the ease synthesis and storage for the marketing.
In the field of cancer treatments, aptamers have been studied as tumor-specific agents driving drugs into cancer cells; additionally
they have been used as anti-neoplastic agents, able to inhibit tumor cell growth and dissemination when administered alone or in combination
with conventional anti-neoplastic drugs. Aptamers are gaining an increased interest for pharmaceutical companies and some of
them are under clinical evaluation trials.
In this review we update the findings about the use of aptamers as “escort” molecules able to drive drugs into the cells and as antineoplastic
drugs. Current anti-neoplastic treatments suffer from the intrinsic toxicity related to the un-specific targeting of both normal
and tumorigenic proliferating cells. The aptamers could be useful to improve: 1) the selective targeting of molecules essential for the viability
and expansion of tumor cells and/or the selective driving of chemotherapies into tumor cells, thus resulting in higher effectiveness
and lower systemic side-effects compared to conventional anti-neoplastic drugs alone and 2) to improve the therapeutic index of currently
used chemotherapies. Even if some problems related to the in vivo stability and pharmacokinetic/dynamics of aptamers remain to be improved,
their potential use in the treatment of different human cancers is getting closer and closer to a practical therapeutic use.
Keywords: Aptamer, chemical analogues, SELEX, drug delivery, tumors, PSMA, nucleolin, eEF1A.
Rights & PermissionsPrintExport